Pfizer (PFE) Aktienübersicht
Pfizer Inc. erforscht, entwickelt, produziert, vermarktet, vertreibt und verkauft biopharmazeutische Produkte in den Vereinigten Staaten und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 5/6 |
Belohnungen
Risikoanalyse
Last Earnings Call
Q2 2026 · 4 Aug 2026Pfizer Inc. reported strong second-quarter 2026 financial results on August 4, 2026, driven by solid performance in its non-COVID portfolio. The company achieved revenues of $15.0 billion, a 1% operational increase year-over-year, with a 5% operational growth in its underlying non-COVID business. Adjusted diluted EPS was $0.77.
Management raised the midpoint of its full-year 2026 revenue guidance by $500 million to a new range of $60.5–$62.5 billion, while reaffirming its adjusted diluted EPS guidance of $2.80–$3.00. Pfizer also announced an additional $2.5 billion in cost-savings initiatives for 2027–2029, bringing the total expected net savings to approximately $9.7 billion through 2029.
Analyst Consensus vs. Actuals
- Revenue: Actual $15.03 billion vs. consensus ~$14.40 billion (Beat)
- EPS: Actual $0.77 vs. consensus ~$0.68 (Beat)
Market Reaction
Pfizer's stock rose approximately 1.86% to $25.50 on August 4, 2026. Investors reacted positively to the "double beat" on earnings and revenue, as well as the raised full-year revenue guidance, which signaled continued momentum in core non-COVID commercial products despite declining pandemic-era revenue.
PFE Community Fair Values
Create NarrativeSee what 990 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Pfizer Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$26.76 |
| 52-Wochen-Hoch | US$28.75 |
| 52-Wochen-Tief | US$23.58 |
| Beta | 0.28 |
| 1 Monat Veränderung | 10.72% |
| 3 Monate Veränderung | 3.68% |
| 1 Jahr Veränderung | 8.87% |
| 3 Jahre Veränderung | -25.75% |
| 5 Jahre Veränderung | -44.80% |
| Veränderung seit IPO | 5,805.67% |
Aktuelle Nachrichten und Updates
Recent updates
PFE: Pipeline Readouts And Legal Overhang Will Shape Post Covid Earnings Trajectory
The analyst fair value estimate for Pfizer has risen from $24.00 to $25.00 as analysts factor in updated pipeline expectations, modestly stronger profit margin assumptions, and recent Street price target moves that cluster in the mid to high $20s per share. Analyst Commentary Recent Street views on Pfizer sit in a fairly tight range in the mid to high US$20s, with most price targets clustered between US$25 and US$35.Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far
Summary I initiate Pfizer with a contrarian BUY rating and a $32 price target for 2026 Q3-Q4. PFE’s non-COVID portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth despite patent cliffs. Padcev’s July 2026 approval expands its addressable market, while pipeline assets like Berobenatide and PF-08634404 offer additional upside. Valuation reflects patent-cliff risk, but strong cash flow, dividend support, and underappreciated pipeline provide a favorable risk/reward setup. Read the full article on Seeking Alpha
PFE: Oncology And Obesity Pipeline Will Drive Post Patent Cliff Repricing
Pfizer's analyst price target has edged lower by about $0.80, reflecting updated models that factor in softer revenue expectations, slightly higher long term margin assumptions, and a reset of near term enthusiasm following multiple target cuts and a downgrade to Hold from several firms ahead of upcoming earnings catalysts. Analyst Commentary Recent research on Pfizer points to a mix of caution and optimism, with several firms trimming price targets while still seeing room for the stock to re-rate as execution on the core portfolio, business development and upcoming data readouts play through.PFE: Oncology And Obesity Pipeline Progress Will Balance Patent Cliff Risks
Pfizer's analyst price target edges up by $1 to $26, as analysts point to a more balanced risk and reward profile supported by recent guidance commentary, oncology pipeline milestones, and updated views on longer term revenue and margin assumptions. Analyst Commentary Recent research coverage around Pfizer highlights a mix of upgraded ratings, modest price target increases and ongoing questions around specific product exposures and partnership choices.Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions
Pfizer (PFE) is back in focus after the company said Chief Financial Officer Dave Denton will leave in August, with long-time finance executive Cecile Guegan stepping in as interim CFO during the search for a successor. See our latest analysis for Pfizer. The CFO announcement comes as Pfizer shares trade at US$25.21, with the stock down over the past quarter but posting a 12.52% total shareholder return over the last year. This suggests that shorter term momentum has cooled even as income and...PFE: Oncology And Obesity Pipeline Will Support Post Patent Cliff Repricing
Narrative update Pfizer's analyst price targets have inched higher, with a recent move such as Wolfe Research lifting its view to $26 from $25 as analysts factor in elements like the five-year sales outlook and extended Vyndamax exclusivity, while also accounting for COVID-related uncertainty in their updated assumptions. Analyst Commentary Recent Street commentary on Pfizer centers on two themes investors should keep in mind: how analysts are framing post COVID revenue visibility and how legal and partnership developments may affect long term cash flow and valuation support.
PFE: Obesity And Oncology Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged Pfizer's implied fair value slightly higher to about $29.19 per share, reflecting a series of mostly modest price target increases, including Wolfe Research's move to $26. This comes alongside updated views on long term sales, COVID uncertainty, patent settlements around Vyndamax, and the recent Veppanu licensing, as well as GLP-1 and oncology pipeline commentary.PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.Aktionärsrenditen
| PFE | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 7.0% | 1.8% | 4.2% |
| 1Y | 8.9% | 58.5% | 20.6% |
Rendite im Vergleich zur Industrie: PFE unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 58.5% erzielte.
Rendite vs. Markt: PFE hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.6 erzielte.
Preisvolatilität
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: PFE hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: PFEDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1849 | 75,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. erforscht, entwickelt, produziert, vermarktet, vertreibt und verkauft biopharmazeutische Produkte in den Vereinigten Staaten und international. Das Unternehmen ist in drei Segmenten tätig: Biopharma, PC1, und Pfizer Ignite. Das Unternehmen bietet Produkte für die innere Medizin an, darunter Produkte für kardiovaskuläre Stoffwechselkrankheiten unter der Marke Eliquis, Migräneprodukte unter den Marken Nurtec ODT/Vydura und Zavzpret, Impfstoffe unter den Marken Prevnar, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac und Trumenba sowie Paxlovid für die Behandlung von COVID-19.
Pfizer Inc.'s Grundlagenzusammenfassung
| PFE grundlegende Statistiken | |
|---|---|
| Marktanteil | US$152.52b |
| Gewinn(TTM) | US$4.34b |
| Umsatz(TTM) | US$63.70b |
Ist PFE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| PFE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$63.70b |
| Kosten der Einnahmen | US$16.11b |
| Bruttogewinn | US$47.59b |
| Sonstige Ausgaben | US$43.25b |
| Gewinn | US$4.34b |
Zuletzt gemeldete Gewinne
Jun 28, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.76 |
| Bruttomarge | 74.72% |
| Nettogewinnspanne | 6.81% |
| Schulden/Eigenkapital-Verhältnis | 74.3% |
Wie hat sich PFE auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Zahlt PFE eine zuverlässige Dividende?
Siehe PFE Dividendenhistorie und Benchmarks| Pfizer Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 24 2026 |
| Datum der Dividendenzahlung | Sep 01 2026 |
| Tage bis Ex-Dividende | 17 days |
| Tage bis zum Datum der Dividendenzahlung | 22 days |
Zahlt PFE eine zuverlässige Dividende?
Siehe PFE Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/09 21:44 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/06/28 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Pfizer Inc. wird von 44 Analysten beobachtet. 25 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |